MedPath

Assessment of QUAlity of life during long-term treatment of ToLVapatan in refractory heart failure.(AQUA-TLV)

Not Applicable
Conditions
heart failure
Registration Number
JPRN-UMIN000009604
Lead Sponsor
niversity of Tokyo Hospital
Brief Summary

Tolvaptan arm had significantly improved quality of life compared with the control arm

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
28
Inclusion Criteria

Not provided

Exclusion Criteria

1) serum sodium concentration over 145mEq/L 2) patients who were administered tolvaptan before admission 3) patients who had received mechanical devices 4) patients with acute coronary syndrome 5) patients with future surgical procedure 6) patients with anuria 7) patients unable to drink 8) patients unable to take medicine orally 9) patients with urine osmolality under 350 mOsm/

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
QOL score (Minnesota Living With Heart Failure Questionnaire)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath